摘要
临床上大都采用对症治疗的方式治疗新型冠状病毒肺炎(COVID-19),对于新型冠状病毒尚无特效抑制药物。现通过对既往复方甘草酸苷用于严重急性呼吸综合征(SARS)治疗的有效性和安全性的总结,以期为复方甘草酸苷抗击新型冠状病毒肺炎提供理论依据。
At present,symptomatic treatment is mostly used in the clinic,and there is no effective inhibitory drug for COVID-19.Therefore,it is an important task to provide alternative drug,which is safe and effective in the clinical.We summarized the effectiveness and safety of reciprocating glycyrrhizin in the treatment of severe acute respiratory syndrome,in order to provide theoretical evidence for compound glycyrrhizin to resist COVID-19.
作者
杨磊
刘佳琦
边原
陈岷
童荣生
唐俊晖
范玉婷
蔡璐璐
YANG Lei;LIU Jiaqi;BIAN Yuan;CHEN Min;TONG Rongsheng;TANG Junhui;FAN Yuting;CAI Lulu(School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,610054 P.R.China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu,Sichuan,610072 P.R.China;Chengdu Medical College,Chengdu,Sichuan,610500 P.R.China)
出处
《华西药学杂志》
CAS
CSCD
2020年第3期342-346,共5页
West China Journal of Pharmaceutical Sciences
基金
四川省中医药管理局研究基金(2018QN004)
2020年第一批应对新型冠状病毒科技攻关应急项目(2020YFS0006)
四川省科学技术厅重点研究发展计划(2019YFS0514)。
